Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cara Therapeutics Inc CARA

Healthcare Cannabis
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated... see more

Recent & Breaking News (NDAQ:CARA)

Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

GlobeNewswire December 3, 2019

Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA(TM) in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus

GlobeNewswire December 3, 2019

Cara Therapeutics to Present at November Investor Conferences

GlobeNewswire November 12, 2019

Cara Therapeutics Announces Publication of Difelikefalin (KORSUVA(TM) Injection) KALM(TM)-1 Phase 3 Trial Results in the New England Journal of Medicine

GlobeNewswire November 11, 2019

Cara Therapeutics Reports Third Quarter 2019 Financial Results

GlobeNewswire November 5, 2019

Cara Therapeutics Announces Presentations at Kidney Week 2019

GlobeNewswire November 1, 2019

Cara Therapeutics to Announce Third Quarter 2019 Financial Results on November 5, 2019

GlobeNewswire October 29, 2019

Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVA(TM) Injection in Hemodialysis Patients with Pruritus

GlobeNewswire October 14, 2019

Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 26, 2019

Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA(TM)

PR Newswire August 21, 2019

Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation Technology

GlobeNewswire August 21, 2019

Cara Therapeutics Reports Second Quarter 2019 Financial Results

GlobeNewswire August 7, 2019

Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019

GlobeNewswire July 31, 2019

Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire July 29, 2019

Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock

GlobeNewswire July 24, 2019

Cara Therapeutics Announces Proposed Offering of Common Stock

GlobeNewswire July 24, 2019

Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVA(TM) in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment

GlobeNewswire July 22, 2019

Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA(TM) for Pruritus in Patients with Atopic Dermatitis

PR Newswire July 11, 2019

Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA(TM) (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis

GlobeNewswire July 9, 2019

Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Second Pruritus Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA(TM)

PR Newswire June 27, 2019